SOURCE: Easton Pharmaceuticals Inc

Easton Pharmaceuticals Inc

February 05, 2015 09:00 ET

Easton Pharmaceuticals Releases December Vaporizer Sales, Highlighting a 62% Month Over Month Increase in Revenues on Fiscal 2014 Vaporizer Segment Revenues

NEW YORK, NY--(Marketwired - Feb 5, 2015) - Easton Pharmaceuticals (OTC PINK: EAPH) announces December Vaporizer sales highlighting a 62% month over month increase in revenues as it relates to www.ecigmarkets.com, a wholly owned Vaporizer unit of Easton Pharmaceuticals Inc.

The Vaporizer business showed a month over month increase with sales of $41,789.94 for the month of December. A 61% increase in sales from the prior month's sales of $25,638.00 in November 2014. Gross margins averaged 55% for December 2014 mainly due to lack of discounting. Increase in sales attributable to rise in associated SEO marketing campaigns. Total sales since inception of vaporizer business lines in fiscal 2014, have directly resulted in $67,428.94 in gross revenues. Month end Vaporizer inventory on hand was shown to be $4,956.00.

Currently the most popular brand has been the following unit, and as such Easton plans to expand its relationship with Davinci vaporizers in the coming days:
http://ecigmarkets.com/product/davinci-vaporizer/

The DaVinci Vaporizer combines a feature rich platform with rugged portability. Our most popular model in the DaVinci line, which is offered in a very appealing and popular black matte finish.

Medicated Markets has updated its website www.medicatedmarkets.com as well as included updates on its current cloning efforts on its twitter feed https://twitter.com/medimarkets. Many shareholders have requested revenue estimates as it relates to Easton / Medicated Markets partnership venture. Those numbers are expected to not be available for at least 1 more week until all clones have shown proper rooting progress. An update on current wholesale marijuana pricing in California as it relates to current dispensary partners should also be forthcoming by early next week.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and other industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns an interest in a topically-delivered cancer drug and other OTC therapeutic products that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
www.medicatedmarkets.com

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact Information